2024年2月21日 · We evaluated 15 patients with severe SLE (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single infusion of CD19 chimeric antigen...

2016年6月30日 · CD19-targeted CAR constructs from several different institutions have demonstrated consistently high antitumor efficacy in children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (B-NHL).

CD19-targeted chimeric antigen receptors (CD19 CARs) have opened a path for novel immune therapies in oncology and other fields of medicine. This therapeutic innovation is predicated on advances in genetic engineering, tumor immunology and cell manufacturing sciences [1 – 4].

2024年2月1日 · In this issue of Blood, Abramson et al 1 present follow-up data from TRANSCEND, redemonstrating robust and ongoing responses from the largest pivotal cohort of CD19 chimeric antigen receptor (CAR)-T–treated patients to date.

We report cryo-EM structures of CD19 antigen with the binder FMC63 which is used in four FDA-approved CAR T cell therapies (Kymriah, Yescarta, Tecartus, Breyanzi), and the binder SJ25C1 which has also been used extensively in multiple clinical trials.

2024年8月27日 · Third-generation chimeric antigen receptor T cells (CARTs) for relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) may improve efficacy compared to second-generation CARTs due to their...

2021年6月22日 · We developed a humanized CD19 CAR based on the backbone of CTL019 (now known as tisagenlecleucel), with the hypothesis that it would have a lower risk of immunogenicity than a murine-based CAR and show improved persistence.

2025年1月20日 · C D19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, this therapy brings a new approach in resetting immune dysregulation and potentially providing long-term …

4 天之前 · Background: GCC19CART, the first clinical candidate from the CoupledCAR solid tumor platform, pairs solid tumor CAR T-cells with CD19-targeting CAR T-cells to enhance proliferation, activation, and persistence against solid tumors. GCC19CART targets guanylate cyclase-C (GCC), a known mucosal marker. Building on the promising results from a clinical …

3 天之前 · Anti-CD19 + chimeric antigen receptor T-cell (CART) therapy is a breakthrough oncologic advance because of remarkable effectiveness and durable responses. 1 Utilization has accelerated in the United States after the initial US Food and Drug Administration (FDA) approval in 2017 for several indications in B-cell malignancies. The current generation of CART …